Hepatitis C Virus

A. J. Thompson; P. Clark; A. Aghemo

doi:10.1016/B978-0-12-386882-4.00037-2

Hepatitis C Virus

A. J. Thompson, P. Clark, A. Aghemo

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

In 2009, genome-wide association studies identified key roles for IL28B and ITPA polymorphisms in predicting HCV treatment outcomes using pegylated interferonα and ribavirin therapy. The IL28B polymorphism is strongly associated with antiviral efficacy of interferon-based HCV therapy, as well as with the spontaneous clearance of acute HCV infection. Very recently, it was proposed that IL28B polymorphisms actually tag a functional variant that affects the novel IFNL4 gene. Two functional ITPA variants determine the risk of ribavirin-induced hemolytic anemia. Personalized medicine is now a reality for chronic HCV patients, and IL28B genotyping has been incorporated into the clinical algorithm for individuals considering antiviral therapy.

Original language	English
Title of host publication	Handbook of Pharmacogenomics and Stratified Medicine
Publisher	Elsevier Inc.
Pages	859-877
Number of pages	19
ISBN (Print)	9780123868831, 9780123868824
DOIs	https://doi.org/10.1016/B978-0-12-386882-4.00037-2
Publication status	Published - May 6 2014

Keywords

Anemia
IFNL4
IL28B
Inosine triphosphatase
Interferon
Interleukin-28B
ITPA
Lambda
Ribavirin

ASJC Scopus subject areas

Medicine(all)
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1016/B978-0-12-386882-4.00037-2

Fingerprint Dive into the research topics of 'Hepatitis C Virus'. Together they form a unique fingerprint.

Cite this

Thompson, A. J., Clark, P., & Aghemo, A. (2014). Hepatitis C Virus. In Handbook of Pharmacogenomics and Stratified Medicine (pp. 859-877). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-386882-4.00037-2

@inbook{16f5d96585264a05a47756d43c9e3349,

title = "Hepatitis C Virus",

abstract = "In 2009, genome-wide association studies identified key roles for IL28B and ITPA polymorphisms in predicting HCV treatment outcomes using pegylated interferonα and ribavirin therapy. The IL28B polymorphism is strongly associated with antiviral efficacy of interferon-based HCV therapy, as well as with the spontaneous clearance of acute HCV infection. Very recently, it was proposed that IL28B polymorphisms actually tag a functional variant that affects the novel IFNL4 gene. Two functional ITPA variants determine the risk of ribavirin-induced hemolytic anemia. Personalized medicine is now a reality for chronic HCV patients, and IL28B genotyping has been incorporated into the clinical algorithm for individuals considering antiviral therapy.",

keywords = "Anemia, IFNL4, IL28B, Inosine triphosphatase, Interferon, Interleukin-28B, ITPA, Lambda, Ribavirin",

author = "Thompson, {A. J.} and P. Clark and A. Aghemo",

year = "2014",

month = may,

day = "6",

doi = "10.1016/B978-0-12-386882-4.00037-2",

language = "English",

isbn = "9780123868831",

pages = "859--877",

booktitle = "Handbook of Pharmacogenomics and Stratified Medicine",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Hepatitis C Virus

AU - Thompson, A. J.

AU - Clark, P.

AU - Aghemo, A.

PY - 2014/5/6

Y1 - 2014/5/6

N2 - In 2009, genome-wide association studies identified key roles for IL28B and ITPA polymorphisms in predicting HCV treatment outcomes using pegylated interferonα and ribavirin therapy. The IL28B polymorphism is strongly associated with antiviral efficacy of interferon-based HCV therapy, as well as with the spontaneous clearance of acute HCV infection. Very recently, it was proposed that IL28B polymorphisms actually tag a functional variant that affects the novel IFNL4 gene. Two functional ITPA variants determine the risk of ribavirin-induced hemolytic anemia. Personalized medicine is now a reality for chronic HCV patients, and IL28B genotyping has been incorporated into the clinical algorithm for individuals considering antiviral therapy.

AB - In 2009, genome-wide association studies identified key roles for IL28B and ITPA polymorphisms in predicting HCV treatment outcomes using pegylated interferonα and ribavirin therapy. The IL28B polymorphism is strongly associated with antiviral efficacy of interferon-based HCV therapy, as well as with the spontaneous clearance of acute HCV infection. Very recently, it was proposed that IL28B polymorphisms actually tag a functional variant that affects the novel IFNL4 gene. Two functional ITPA variants determine the risk of ribavirin-induced hemolytic anemia. Personalized medicine is now a reality for chronic HCV patients, and IL28B genotyping has been incorporated into the clinical algorithm for individuals considering antiviral therapy.

KW - Anemia

KW - IFNL4

KW - IL28B

KW - Inosine triphosphatase

KW - Interferon

KW - Interleukin-28B

KW - ITPA

KW - Lambda

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=84942134100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942134100&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-386882-4.00037-2

DO - 10.1016/B978-0-12-386882-4.00037-2

M3 - Chapter

AN - SCOPUS:84942134100

SN - 9780123868831

SN - 9780123868824

SP - 859

EP - 877

BT - Handbook of Pharmacogenomics and Stratified Medicine

PB - Elsevier Inc.

ER -